Breast cancer: Seno Medical hits 100th patient in Imagio pivotal trial

November 25, 2013 by Arezu Sarvestani

Texas-based Seno Medical enrolls its 1st 100 patients in a pivotal study of its Imagio opto-acoustic imaging system, which aims to avoid false-positives that result in unnecessary biopsies.

Breast cancer: Seno Medical hits 100th patient in Imagio imaging trial

Seno Medical Instruments touted the 100th patient enrolled in a pivotal clinical study of the company's Imagio system, an opto-acoustic breast imaging platform designed to help prevent unnecessary biopsies.

The Imagio system combines traditional ultrasound with light-based imaging, providing physicians with a closer look at "suspicious" breast masses without subjecting patients to radiation, injectable contrast agents or invasive biopsies.

Sign up to get our free newsletters delivered right to your inbox.

"Scanning the 1st 100 patients and starting the active enrollment phase is an important milestone for us in our mission to deliver a new standard in breast cancer diagnosis," Seno CEO Janet Campbell said in prepared remarks. "We believe Imagio can offer a better diagnostic alternative for women who have suspicious breast masses, and can help physicians more confidently rule out cancer with a less invasive test."

There are about 1.7 million surgical breast biopsies performed in the U.S. yearly, 80% of which reveal benign tissue, according to the company. As the most costly part of breast cancer diagnosis, avoiding unnecessary biopsies may be able to bring down the cost of care and prevent patients from undergoing needless invasive procedures.